André Zimerman
@andrezimerman.bsky.social
Cardiologist, MD, PhD | Head, Clinical Trials Unit (ARO), Hosp. Moinhos de Vento 🇧🇷 | Professor, Postgrad Cardiology, UFRGS 🇧🇷 | Fellowship, TIMI Study Group, BWH/HMS 🇺🇸 | Lipids, Trials, Cardiology
In summary, for patients requiring lipid-lowering meds:
i) There is *no* evidence of cognitive impairment over the longer term
ii) The proven cardiovascular benefits of lowering LDL-C must outweigh any speculative risks
Link: evidence.nejm.org/doi/full/10....
i) There is *no* evidence of cognitive impairment over the longer term
ii) The proven cardiovascular benefits of lowering LDL-C must outweigh any speculative risks
Link: evidence.nejm.org/doi/full/10....
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
Concerns persist regarding the cognitive safety of achieving very low levels of low-density
lipoprotein (LDL) cholesterol. Although short-term studies are reassuring, the long-term
cognitive effect...
evidence.nejm.org
December 26, 2024 at 11:26 PM
In summary, for patients requiring lipid-lowering meds:
i) There is *no* evidence of cognitive impairment over the longer term
ii) The proven cardiovascular benefits of lowering LDL-C must outweigh any speculative risks
Link: evidence.nejm.org/doi/full/10....
i) There is *no* evidence of cognitive impairment over the longer term
ii) The proven cardiovascular benefits of lowering LDL-C must outweigh any speculative risks
Link: evidence.nejm.org/doi/full/10....
3⃣ No meaningful differences between the two originally randomized groups over time.
December 26, 2024 at 11:26 PM
3⃣ No meaningful differences between the two originally randomized groups over time.
2⃣ No association between cognitive change and LDL-C in patients who transitioned to evolocumab.
(Even in patients with LDL-C <25 mg/dL.)
(Even in patients with LDL-C <25 mg/dL.)
December 26, 2024 at 11:26 PM
2⃣ No association between cognitive change and LDL-C in patients who transitioned to evolocumab.
(Even in patients with LDL-C <25 mg/dL.)
(Even in patients with LDL-C <25 mg/dL.)
1⃣ There was no meaningful cognitive decline up to 7.2 years of follow-up.
December 26, 2024 at 11:26 PM
1⃣ There was no meaningful cognitive decline up to 7.2 years of follow-up.
Now, for the first time, we followed:
- Hundreds of patients
- For over 7 years
- On evolocumab + statin (median LDL-C ~35 mg/dL)
This is an open-label extension analysis of the EBBINGHAUS study from the FOURIER trial.
These are the 3 takeaways 👇
- Hundreds of patients
- For over 7 years
- On evolocumab + statin (median LDL-C ~35 mg/dL)
This is an open-label extension analysis of the EBBINGHAUS study from the FOURIER trial.
These are the 3 takeaways 👇
December 26, 2024 at 11:26 PM
Now, for the first time, we followed:
- Hundreds of patients
- For over 7 years
- On evolocumab + statin (median LDL-C ~35 mg/dL)
This is an open-label extension analysis of the EBBINGHAUS study from the FOURIER trial.
These are the 3 takeaways 👇
- Hundreds of patients
- For over 7 years
- On evolocumab + statin (median LDL-C ~35 mg/dL)
This is an open-label extension analysis of the EBBINGHAUS study from the FOURIER trial.
These are the 3 takeaways 👇
Many "influencers" say that lipid-lowering therapies cause dementia.
This is despite the fact that brain cells generate their own cholesterol.
And despite reassuring short-term randomized trials.
This is despite the fact that brain cells generate their own cholesterol.
And despite reassuring short-term randomized trials.
December 26, 2024 at 11:26 PM
Many "influencers" say that lipid-lowering therapies cause dementia.
This is despite the fact that brain cells generate their own cholesterol.
And despite reassuring short-term randomized trials.
This is despite the fact that brain cells generate their own cholesterol.
And despite reassuring short-term randomized trials.